中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2012年
2期
110-116
,共7页
闵敏%林莉%毕成峰%王晓卿%罗添友%赵莎%张文燕%刘卫平
閔敏%林莉%畢成峰%王曉卿%囉添友%趙莎%張文燕%劉衛平
민민%림리%필성봉%왕효경%라첨우%조사%장문연%류위평
中枢神经系统肿瘤%淋巴瘤,B细胞%免疫组织化学%预后
中樞神經繫統腫瘤%淋巴瘤,B細胞%免疫組織化學%預後
중추신경계통종류%림파류,B세포%면역조직화학%예후
=Central nervous system neoplasms%Lymphoma,B-cell%Immunohistochemistry%Prognosis
目的 对原发性中枢神经系统弥漫大B细胞淋巴瘤(CNS DLBCL)进行Hans、Choi和Tally分型比较研究,探讨其与预后的关系.方法 应用免疫组织化学染色技术检测CD20、CD3、CD10、Bcl-6、Mum-1、CD5、Bcl-2、Ki-67、FOXP-1、GCET-1、BLIMP-1和LMO-2在47例CNS DLBCL中的表达,并进行Hans、Choi和Tally分型,分析其与预后的关系.结果 47例CNS DLBCL中,Bcl-2、CD10、Bcl-6、Mum-1、GCET-1、BLIMP-1、FOXP-1和LMO-2的表达率分别为46.8％、4.3％、70.2％、53.2％、36.2％、4.3％、63.8％和19.2％；Ki-67的阳性率为30％～95％,中位数为80％,其中12例(25.5％)≥90％.Hans分型中,生发中心B细胞(GCB)型16例(34.0％),非生长中心B细胞(nonGCB)型31例(66.0％)；Choi分型中,GCB型16例(34.0％),活化B细胞(ABC)型31例(6.0％)；Tally分型中,GCB型6例(12.8％),non-GCB型41例(87.2％).47例CNS DLBCL患者的１、2和5年生存率分别为34.0％、15.6％和12.5％.Hans、Choi和Tally分型不影响CNS DLBCL患者预后的相关因素(均P＞0.05).结论 Hans、Choi和Tally分型与CNS DLBCL的预后均无明显相关性.术后放化疗和甲氨蝶呤治疗与预后相关.
目的 對原髮性中樞神經繫統瀰漫大B細胞淋巴瘤(CNS DLBCL)進行Hans、Choi和Tally分型比較研究,探討其與預後的關繫.方法 應用免疫組織化學染色技術檢測CD20、CD3、CD10、Bcl-6、Mum-1、CD5、Bcl-2、Ki-67、FOXP-1、GCET-1、BLIMP-1和LMO-2在47例CNS DLBCL中的錶達,併進行Hans、Choi和Tally分型,分析其與預後的關繫.結果 47例CNS DLBCL中,Bcl-2、CD10、Bcl-6、Mum-1、GCET-1、BLIMP-1、FOXP-1和LMO-2的錶達率分彆為46.8％、4.3％、70.2％、53.2％、36.2％、4.3％、63.8％和19.2％；Ki-67的暘性率為30％～95％,中位數為80％,其中12例(25.5％)≥90％.Hans分型中,生髮中心B細胞(GCB)型16例(34.0％),非生長中心B細胞(nonGCB)型31例(66.0％)；Choi分型中,GCB型16例(34.0％),活化B細胞(ABC)型31例(6.0％)；Tally分型中,GCB型6例(12.8％),non-GCB型41例(87.2％).47例CNS DLBCL患者的１、2和5年生存率分彆為34.0％、15.6％和12.5％.Hans、Choi和Tally分型不影響CNS DLBCL患者預後的相關因素(均P＞0.05).結論 Hans、Choi和Tally分型與CNS DLBCL的預後均無明顯相關性.術後放化療和甲氨蝶呤治療與預後相關.
목적 대원발성중추신경계통미만대B세포림파류(CNS DLBCL)진행Hans、Choi화Tally분형비교연구,탐토기여예후적관계.방법 응용면역조직화학염색기술검측CD20、CD3、CD10、Bcl-6、Mum-1、CD5、Bcl-2、Ki-67、FOXP-1、GCET-1、BLIMP-1화LMO-2재47례CNS DLBCL중적표체,병진행Hans、Choi화Tally분형,분석기여예후적관계.결과 47례CNS DLBCL중,Bcl-2、CD10、Bcl-6、Mum-1、GCET-1、BLIMP-1、FOXP-1화LMO-2적표체솔분별위46.8％、4.3％、70.2％、53.2％、36.2％、4.3％、63.8％화19.2％；Ki-67적양성솔위30％～95％,중위수위80％,기중12례(25.5％)≥90％.Hans분형중,생발중심B세포(GCB)형16례(34.0％),비생장중심B세포(nonGCB)형31례(66.0％)；Choi분형중,GCB형16례(34.0％),활화B세포(ABC)형31례(6.0％)；Tally분형중,GCB형6례(12.8％),non-GCB형41례(87.2％).47례CNS DLBCL환자적１、2화5년생존솔분별위34.0％、15.6％화12.5％.Hans、Choi화Tally분형불영향CNS DLBCL환자예후적상관인소(균P＞0.05).결론 Hans、Choi화Tally분형여CNS DLBCL적예후균무명현상관성.술후방화료화갑안접령치료여예후상관.
Objective To analyze the subtypes of primary diffuse large B cell lymphoma of the central nervous system (CNS DLBCL) and to explore the relationship between the subtype classification and prognosis.Methods Immunohistochemical staining was used to determine the expression of CD20,CD3,CD10,Bcl-6,Mum-1,CD5,Bcl-2,Ki-67,FOXP-1,GCET-1,BLIMP-1 and LMO-2 antigens on paraffinembedded sections of 47 cases. Hans,Choi and Tally subtypes were classified,and univariate and multivariate analyses were used to elucidate the relationship between the subtypes and prognosis.Results In the 47 cases,the expression of Bcl-2 in the tumor cells was 46.8％,CD10 4.3％,Bcl-6 70.2％,Mum-1 53.2％,GCET-1 36.2％,BLIMP-1 4.3％,FOXP-1 63.8％ and LMO-2 19.2％.The positive rate of Ki-67 was 30％ to 95％,with a median of 80％,of which 12 cases (25.5％) was ≥ 90％.The Hans subtype classification showed 16 cases (34.0％) were of GCB type and 31 cases (66.0％) of non-GCB type.The Choi subtype classification showed 16 cases (34.0％) were of GCB type and 31 cases (66.0％) of ABC type.The Tally subtype classification showed 6 cases ( 12.8％ ) were of GCB type and 41 cases (87.2％)of non-GCB type.Conclusions The results of this study show that there is no significant correlation between the three subtypes and prognosis.The prognosis is correated with post-operative radiotherapy,chemotherapy and MTX therapy.
